REC-2282 not checked

Recursion Pharmaceuticals Inc. · AR-42 · OSU-HDAC42

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive REC-2282 3 times per week orally for 3 weeks followed by 1 week off for a 4-week cycle.”In the company’s words, NCT05130866 on ClinicalTrials.gov
Tested for
Neurofibromatosis Type 2
Main trialPhase 2/3
“This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in participants with progressive NF2 mutated meningiomas.”In the company’s words, NCT05130866 on ClinicalTrials.gov
Other names
AR-42 · OSU-HDAC42 · NSC-D736012

Other drugs for Neurofibromatosis Type 2

All 1 drugs for Neurofibromatosis Type 2

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2/3Terminated 18 Aug 2025 Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow REC-2282

Following is part of Solo: you see every change to REC-2282 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in